Predictive factors for adverse outcome of pedal bypasses

Eur J Vasc Endovasc Surg. 1999 Aug;18(2):138-43. doi: 10.1053/ejvs.1999.0875.

Abstract

Objective: to identify the risk factors affecting the outcome of bypass grafts to the foot arteries.

Design: longitudinal observational study from a single institution.

Materials and methods: one-hundred and sixty-five infrainguinal bypasses to the foot arteries were performed in 162 legs of 149 patients with critical leg ischaemia.

Results: at 1-month, 1-year, 2-year and 3-year follow-up, the primary patency rates were 74%, 43%, 38% and 34%, the secondary patency rates were 82%, 50%, 47% and 41%, the leg salvage rates were 88%, 66%, 66% and 60%, survival rates were 95%, 76%, 69% and 55%, whereas 82%, 53%, 49% and 36% of patients were alive with salvaged leg, respectively. Low preoperative plasma concentrations of C-reactive protein (CRP) and short grafts with more distal arterial inflow had a better outcome. Better primary and secondary patency rates were also achieved by experienced surgeons and by the use of in situ saphenous vein grafts. Pedal run-off scoring did not have any impact on the outcome of pedal bypasses.

Conclusions: short pedal bypasses using in situ saphenous vein technique, done by an experienced surgeon, have the best outcome. Revascularisation to the foot arteries may carry a poor outcome in patients with elevated preoperative CRP concentration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiography
  • Blood Vessel Prosthesis
  • C-Reactive Protein / analysis
  • Chi-Square Distribution
  • Female
  • Foot / blood supply*
  • Humans
  • Ischemia / diagnosis
  • Ischemia / surgery*
  • Likelihood Functions
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Proportional Hazards Models
  • Risk Factors
  • Statistics, Nonparametric
  • Survival Analysis
  • Treatment Outcome
  • Vascular Patency
  • Veins / transplantation

Substances

  • C-Reactive Protein